The use of targeted LNP/mRNA technology to generate functional, transient CAR T cells and treat cardiac injury in vivo

References

[1] Rurik JG,Yadegari A.CAR T cells produced in vivo to treat cardiac injury.Science2022;375:91-6

[2] Albinger N,Ullrich E.Current status and perspective of CAR-T and CAR-NK cell therapy trials in Germany.Gene Ther2021;28:513-27 PMCID:PMC8455322

[3] Aghajanian H,Rurik JG.Targeting cardiac fibrosis with engineered T cells.Nature2019;573:430-3 PMCID:PMC6752964

[4] Let's talk about lipid nanoparticles.Nat Rev Mater2021;6:99-99

[5] Weissman D.mRNA transcript therapy.Expert Rev Vaccines2015;14:265-81

[6] Adams D,O'Riordan WD.Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis.N Engl J Med2018;379:11-21

[7] Prata LGPL,Tchkonia T.Senescent cell clearance by the immune system: Emerging therapeutic opportunities.Semin Immunol2018;40:101275 PMCID:PMC7061456

[8] Yousefzadeh MJ,Zhu Y.An aged immune system drives senescence and ageing of solid organs.Nature2021;594:100-5 PMCID:PMC8684299

[9] Lewis-McDougall FC,Domenjo-Vila E.Aged-senescent cells contribute to impaired heart regeneration.Aging Cell2019;18:e12931 PMCID:PMC6516154